NSD2 drives triple-negative breast cancer progression via ATAD3A-dependent senescence. (PubMed, Cell Signal) - Oct 2, 2026 - "Elevated lactate further induced HMGB1 lactylation and enhanced its protein stability, which sequentially activated senescence-associated genes and the senescence-associated secretory phenotype (SASP), consequently promoting epithelial-mesenchymal transition (EMT) and tumor progression. The NSD2 inhibitor KTX-1001 combined with ATAD3A knockdown enhanced the suppression of tumor burden and invasive potential with favorable biosafety.enhancedenhanced This study identifies a novel NSD2-H3K36me2-ATAD3A-Drp1-HMGB1 lactylation axis that drives senescence-associated progression in TNBC, providing a promising epigenetic-metabolic combination therapeutic strategy for this disease."
Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HMGB1 • NSD2
|
|
Huihao Zhang; Jinshu Chen; Kunlin Wu; Wei Lin; Xiangjin Chen; Zhaomei Yu
|